ENA 2026 is a leading forum for drug development and translational cancer research, highlighting cutting-edge preclinical and Phase I studies, emerging molecular targets, and novel therapeutics. The symposium brings together researchers, clinicians, and industry experts from around the world.

START’s Presence: START will join the global early drug development community at ENA 2026. Meet with our team to learn how START’s dedicated early-phase network across the U.S. and Europe supports sponsors from protocol review and activation through enrollment and data generation.